Apellis Pharmaceuticals
APLS
APLS was delisted on the 13th of May, 2026.
255 hedge funds and large institutions have $2.8B invested in Apellis Pharmaceuticals in 2025 Q1 according to their latest regulatory filings, with 49 funds opening new positions, 91 increasing their positions, 76 reducing their positions, and 52 closing their positions.
34% more call options, than puts
Call options by funds: $26.6M | Put options by funds: $19.8M
20% more repeat investments, than reductions
Existing positions increased: 91 | Existing positions reduced: 76
0.1% more ownership
Funds ownership: 101.87% → 101.97% (+0.1%)
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
6% less first-time investments, than exits
New positions opened: 49 | Existing positions closed: 52
2% less funds holding
Funds holding: 260 → 255 (-5)
31% less capital invested
Capital invested by funds: $4.04B → $2.8B (-$1.24B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AQR Capital Management
Greenwich,
Connecticut
|
+$61.4M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$40.1M |
| 3 |
O
OrbiMed
New York
|
+$39.6M |
| 4 |
Canada Pension Plan Investment Board
Toronto Ontario,
Ontario, Canada
|
+$28M |
| 5 |
Man Group
London,
United Kingdom
|
+$27M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CWM
CIBC World Markets
New York
|
-$41M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$40.5M |
| 3 |
OCA
Octagon Capital Advisors
New York
|
-$25.2M |
| 4 |
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
|
-$23.1M |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$20M |
APLS Hedge Fund Activity: Q1 2025 in Review
255 of the 7,464 institutional investors tracked by Wall St. Rank reported a position in Apellis Pharmaceuticals (APLS) for Q1 2025, worth a combined $2.8B — down 31% from $4.04B a quarter earlier.
Sellers outnumbered buyers: 52 funds closed out of APLS and 49 opened new positions — a net loss of 3 holders — while 76 trimmed existing stakes and 91 added.
The largest buyer was AQR Capital Management, adding an estimated $61.4M. The largest seller was CIBC World Markets, exiting entirely with an estimated $41M sold.
- 255 institutional investors held Apellis Pharmaceuticals (APLS) as of Q1 2025, down from 260 in Q4 2024.
- Funds reported $2.8B of Apellis Pharmaceuticals stock for Q1 2025, down 31% quarter-over-quarter.
- 49 funds opened new Apellis Pharmaceuticals positions in Q1 2025 and 52 closed out, a net change of -3 holders.
- The largest Apellis Pharmaceuticals buyer in Q1 2025 was AQR Capital Management, an estimated $61.4M added.
- The largest Apellis Pharmaceuticals seller in Q1 2025 was CIBC World Markets, an estimated $41M sold.
Based on aggregated 13F filings for Q1 2025.